Amgen to buy Celgene’s psoriasis drug Otezla for £10.9bn

This article was originally published here

Otezla is being divested in connection with the ongoing regulatory approval process for the pending merger between Bristol-Myers Squibb and Celgene. The deal may also be valued about

The post Amgen to buy Celgene’s psoriasis drug Otezla for £10.9bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply